Subscribe To

Price Alert Latest News Economic Calendar News

POLBF / Poolbeg Pharma receives initial results from human challenge clinical study

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after receiving the initial results from its LPS human challenge clinical study for its molecule POLB 001, that he hopes will eventually help in treating severe influenza. Skillington says that there were "no severe adverse events" reported among the 36 healthy volunteers. Read More

Demo Live Account See Partner Details

Content Topics

Poolbeg

Pharma

Receives

Initial

Results

From

Human

Challenge

Clinical

Stock

POLBF

Posted: Dec 12 2022, 03:22

Author Name: Proactive Investors

POLBF News

By Proactive Investors
November 3, 2023

Poolbeg's lead asset to be in the spotlight at leading medical conference

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said the potential of its lead asset will be discussed at a leading medical conference in December. A poste

By Proactive Investors
November 1, 2023

Poolbeg investor meeting will take a deep dive into lead programme

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) is hosting an investor and analyst meeting focusing on its POLB 001 Oncology Programme, targeting cytokin

By Proactive Investors
October 26, 2023

Poolbeg advisory board endorses flu drug approach

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said it has secured an endorsement from its scientific advisory board (SAB) of the prioritised targets for

By Proactive Investors
October 17, 2023

Poolbeg Pharma up 8% on deal with Nasdaq biotech

Shares in Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) rose 8% in early trading after the company announced a partnership with an unnamed Nasdaq-listed

By Proactive Investors
October 17, 2023

Poolbeg Pharma inks collaboration agreement with Nasdaq biotech

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said it has inked an agreement with an unnamed Nasdaq-listed biopharmaceutical entity aimed at developing

By Proactive Investors
September 29, 2023

Poolbeg Pharma closes chapter on patent challenge

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF), the clinical-stage biopharmaceutical group, has announced the cancellation of the European Patent Office (

By Proactive Investors
September 20, 2023

Poolbeg Pharma shores up protection around its IP

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF), the clinical-stage biopharmaceutical firm, recently received a notice of allowance from the Japanese Paten

By Proactive Investors
September 19, 2023

Poolbeg Pharma: Third party withdraws patent opposition

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said that an unnamed 'third party' has agreed to withdraw its opposition to one of the company's European

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.